Ariana P. Toepfer

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024

Heidi L. Moline, Ayzsa Tannis, Ariana P. Toepfer et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · 202 citations · Full text

Veterinary Medicine, Infectious Diseases, Pediatrics +17

Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States

Aaron M. Frutos, Ashley M. Price, Elizabeth Harker et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · 86 citations · Full text

Medicine, Infectious Diseases, Pediatrics +17

Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024

Heidi L. Moline, Ariana P. Toepfer, Ayzsa Tannis et al. · JAMA Pediatrics · 2024 · 61 citations · Full text

Public Health, Infectious Diseases, Pediatrics +17

Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025

Monica E. Patton, Heidi L. Moline, Michael Whitaker et al. · MMWR Morbidity and Mortality Weekly Report · 2025 · 34 citations · Full text

Medicine, Infectious Diseases, Pediatrics +17

Respiratory Syncytial Virus-Associated Hospitalizations in Children <5 Years: 2016–2022

Meredith McMorrow, Heidi L. Moline, Ariana P. Toepfer et al. · PEDIATRICS · 2024 · 31 citations · Full text

Veterinary Medicine, Infectious Diseases, Pediatrics +17